1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no treatment-related fatalities among patients in the talazoparib group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer is the second most common malignancy among men. Despite existing therapies, metastatic castration-resistant prostate cancer (mCRPC) remains a
TROY— Troy University biomedical researcher Dr. Jacqueline Jones was recently awarded a $95,000 grant from the Elsa U. Pardee Foundation to conduct research on the factors that drive advanced stages